A Trial to Learn More About How Well BAY2586116 Works and How Safe it is in Participants With Moderate to Severe Obstructive Sleep Apnea

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

August 17, 2021

Study Completion Date

November 11, 2021

Conditions

Sleep Apnea, Obstructive

Interventions

DRUG

BAY2586116

160 µg, nasal spray administration.

DRUG

Placebo

Placebo matching BAY2586116, nasal spray administration.

Trial Locations (3)

UniversitätsSpital Zürich, Zurich

Advanced Sleep Research GmbH, Berlin

Ruhrlandklinik, Westdeutsches Lungenzentrum, Essen